{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:07:21Z","timestamp":1777878441056,"version":"3.51.4"},"reference-count":0,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2025,11]]},"abstract":"Summary<\/jats:title>\n \n What is this summary about?<\/jats:bold>\n <\/jats:p>\n \u2022\u2003This is a summary of a research article published in a medical journal that describes the main results from two studies called TRuE-V1 and TRuE-V2<\/jats:p>\n \n \u2022\u2003These studies looked at the use of\n ruxolitinib<\/jats:bold>\n cream to treat\n vitiligo<\/jats:bold>\n , a long-term condition where white patches develop on the skin\n <\/jats:p>\n \n \u2022\u2003\n Ruxolitinib<\/jats:bold>\n belongs to a group of medicines called Janus kinase (JAK) inhibitors, which have been shown to restore the skin color (also known as skin pigment) of some people with the most common form of\n vitiligo<\/jats:bold>\n (non-\n segmental<\/jats:bold>\n vitiligo<\/jats:bold>\n , also known as generalized\n vitiligo<\/jats:bold>\n or bilateral\n vitiligo<\/jats:bold>\n )\n <\/jats:p>\n \n What happened in the studies?<\/jats:bold>\n <\/jats:p>\n \n \u2022\u2003Researchers who designed the TRuE-V1 and TRuE-V2 studies wanted to understand if\n ruxolitinib<\/jats:bold>\n cream helped to restore the skin color of people with non-\n segmental<\/jats:bold>\n vitiligo<\/jats:bold>\n , compared with an identical cream that did not contain\n ruxolitinib<\/jats:bold>\n . This is called a vehicle cream\n <\/jats:p>\n \n \u2022\u2003In the studies, people aged 12 years and older with non-segmental\n vitiligo<\/jats:bold>\n were randomly chosen to apply either\n ruxolitinib<\/jats:bold>\n cream or vehicle cream to the parts of their body affected by\n vitiligo<\/jats:bold>\n twice a day for 6\u2009months. For every one person that used the vehicle cream, two people used the\n ruxolitinib<\/jats:bold>\n cream\n <\/jats:p>\n \n \u2022\u2003The main goal of the studies was to find out how many people had a 75% improvement in their facial\n vitiligo<\/jats:bold>\n after 6\u2009months\n <\/jats:p>\n \u25cb\u2003This meant that three-quarters of the white patches on the face returned to normal skin color<\/jats:p>\n \u2022\u2003Other goals included measuring:<\/jats:p>\n \n \u25cb\u2003How many people had a 50% improvement in the\n vitiligo<\/jats:bold>\n on their whole body after 6\u2009months\n <\/jats:p>\n \u25a0\u2003This meant that half of the white patches on the whole body returned to normal skin color<\/jats:p>\n \n \u25cb\u2003How many people felt their\n vitiligo<\/jats:bold>\n was less noticeable after 6\u2009months\n <\/jats:p>\n \n \u2022\u2003The study also looked at the side effects of\n ruxolitinib<\/jats:bold>\n cream and the vehicle cream\n <\/jats:p>\n \n What do the results mean?<\/jats:bold>\n <\/jats:p>\n \n \u2022\u2003In both the TRuE-V1 and TRuE-V2 studies, people who used\n ruxolitinib<\/jats:bold>\n cream for 6\u2009months had greater improvements in their\n vitiligo<\/jats:bold>\n compared with those who used the vehicle cream\n <\/jats:p>\n \n \u2022\u2003The most common side effects were acne (red pimples located mainly on the face) and itchy skin where\n ruxolitinib<\/jats:bold>\n cream was applied\n <\/jats:p>\n \n \u2022\u2003Results from the studies suggest that\n ruxolitinib<\/jats:bold>\n cream helps to restore the color of the skin over time in people with non-\n segmental<\/jats:bold>\n vitiligo<\/jats:bold>\n <\/jats:p>","DOI":"10.1177\/20406223251378246","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:19:15Z","timestamp":1762420755000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publication"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2786-0708","authenticated-orcid":false,"given":"David","family":"Rosmarin","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Passeron","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Nice and Centre M\u00e9diterran\u00e9en de M\u00e9decine Mol\u00e9culaire, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Palo Alto Foundation Medical Group, Sunnyvale, Los Angeles, CA, USA"},{"name":"University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[{"name":"The Vitiligo and Pigmentation Institute of Southern California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[{"name":"University of Massachusetts Chan Medical School, Worcester, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Innovative Dermatology, Plano, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Ruer\u2011Mulard","sequence":"additional","affiliation":[{"name":"Office of Mireille Ruer-Mulard, M.D., Martigues, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[{"name":"National Reference Center for Rare Skin Disorders, H\u00f4pital Saint-Andr\u00e9, and Centre National de la Recherche Scientifique Unit\u00e9 Mixte de Recherche 5164, ImmunoConcept, Universit\u00e9 de Bordeaux, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Wolkerstorfer","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"Sun","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Butler","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Henri Mondor University Hospital and Universit\u00e9 Paris-Est Paris Val de Marne, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,6]]},"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251378246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223251378246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251378246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:20:15Z","timestamp":1777591215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223251378246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":0,"alternative-id":["10.1177\/20406223251378246"],"URL":"https:\/\/doi.org\/10.1177\/20406223251378246","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"article-number":"20406223251378246"}}